16/05/2019 02:52:31

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting

REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 abstracts at the ASCO Annual Meeting detailing new insights into precision oncology generated from its commercially available Guardant360 and GuardantOMNI assays, as well as its research-use-only (RUO) LUNAR liquid biopsy.

For patients with advanced cancer, these include multiple investigations of the GuardantOMNI assay’s ability to identify patients who may benefit from treatment with immunotherapy. Additionally, researchers will present Guardant360 data to demonstrate the effectiveness of new targeted drugs, as well as the feasibility of serial ctDNA analysis to rapidly predict treatment response and long-term clinical benefit.

For patients with early stage disease, the presentations include an analytical validation of Guardant’s LUNAR assay (Abstract 3057), as well as a pilot study exploring the LUNAR assay’s ability to identify early-stage colorectal cancer patients who may benefit from adjuvant therapy after undergoing an intervention with curative intent (Abstract 3602). This is a particularly challenging clinical setting for the detection of circulating tumor DNA in blood because patients who have undergone curative-intent interventions typically have little-to-no evidence of disease, and very low residual tumor DNA shedding in circulation.

“Guardant is committed to expanding the benefits of precision oncology across the continuum of care,” said Guardant Health Chief Medical Officer Dr. Richard Lanman. “The new insights we and our research partners will bring to ASCO this year continue to demonstrate the many advantages of blood-based genomic testing over tissue-based genomic testing in support of a blood-first paradigm in early stage and late stage cancer.”

Guardant’s data will be featured in the following presentations at ASCO this year:

Abstract Title

Date

Time

Abstract Number

Analytical validation of a tumor-agnostic integrated multi-analyte

circulating tumor DNA (ctDNA) assay in early stage cancer

6/1

 

8 a.m. - 11 a.m.

3057

Dynamic monitoring of circulating tumor DNA next-generation gene

sequencing as a predictive biomarker of response and progression free

survival after pembrolizumab monotherapy in patients with advanced NSCLC.

6/1

 

8 a.m. - 11 a.m.

3040

Molecular biology and treatment strategies for non-V600 BRAF-mutant

NSCLC

6/1

 

8 a.m. - 11 a.m.

3102

Molecular circulating tumor DNA response to identify long-term survival in

patients receiving immunotherapy with initial radiologic stable disease

6/1

 

8 a.m. - 11 a.m.

2546

Comprehensive genomic profiling of circulating cell-free DNA (cfDNA)

distinguishes focal amplification (amp) from aneuploidy among MET amps

in diverse advanced cancer types

6/1

 

8 a.m. - 11 a.m.

3046

Baseline cfDNA characteristics and evolution of cfDNA profile during

treatment with selective FGFR inhibitor TAS-120

6/1 8 a.m. - 11 a.m.

3056

 

Identification of genomic alterations by circulating tumor DNA in

leiomyosarcoma: A molecular analysis of 73 patients

6/1

 

8 a.m. - 11 a.m.

11044

TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate

efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid

malignancies with FGFR alterations identified by circulating tumor DNA

6/1

 

8 a.m. - 11 a.m.

TPS3156

Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of

metastatic prostate cancer (mPC) patients

6/1

 

1:15 p.m. - 4:15 p.m.

5032

Genomic landscape of metastatic hormone sensitive prostate cancer

(mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by

circulating tumor DNA (ctDNA).

6/1

 

1:15 p.m. - 4:15 p.m

5043

AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic

castration-resistant prostate cancer (mCRPC) treated with high-dose

testosterone.

6/1

 

1:15 p.m. - 4:15 p.m

5058

Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive

biomarkers of survival in MYSTIC: First-line durvalumab (D) ±

tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.

6/2

 

8 a.m. - 11 a.m.

9016

Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib

in patients (pts) with advanced ALK-positive non-small cell lung cancer

(NSCLC)

6/2

 

8 a.m. - 11 a.m.

9019

Longitudinal Analysis of Plasma ALK Mutations During Treatment with

Next-Generation ALK Inhibitors.

6/2

 

8 a.m. - 11 a.m.

9068

Tracking plasma KRAS mutations (m) in lung adenocarcinoma (LUAC)

patients (p)

6/2

 

8 a.m. - 11 a.m.

9055

A plasma-only integrated somatic and epigenomic circulating tumor DNA

(ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).

6/3

 

8 a.m. - 11 a.m.

3602

Updated analysis and impact of plasma-detected microsatellite stability

(MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab

(D) plus tremelimumab (T) and best supportive care (BSC) versus BSC

alone in patients (pts) with refractory metastatic colorectal carcinoma

(rmCRC)

6/3

 

8 a.m. - 11 a.m.

 

3512

Blood-Based Genomic Profiling of cell-free DNA (OMNI) to Identify

Microsatellite Instability, tumor mutational burden and Wnt/B-Catenin

Pathway Alterations in Patients with Gastrointestinal Tract Cancers

6/3

 

8 a.m. - 11 a.m.

 

3552

Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA

selective pressure

6/3

 

8 a.m. - 11 a.m.

3587

Genomic alterations after EGFR blockade in patients with RAS wild-type

metastatic colorectal cancer: Combined tissue and blood-based analysis

from SCRUM-Japan GI-SCREEN and GOZILA

6/3

 

8 a.m. - 11 a.m.

3528

Association between gene fusions and anti-EGFR resistance signature in

colorectal cancer.

6/3

 

8 a.m. - 11 a.m.

3564

Prediction model for detecting Circulating tumor DNA (ctDNA) in

Metastatic Colorectal Cancer (mCRC).

6/3

 

8 a.m. - 11 a.m.

3590

A Landscape of Circulating Tumor DNA in Esophageal Adenocarcinoma and

Squamous Cell Carcinoma.

6/3

 

8 a.m. - 11 a.m.

4070

Blood-Based Next-Generation Sequencing Analysis of Neuroendocrine

Tumors

6/3

 

8 a.m. - 11 a.m.

4110

Circulating tumor DNA dynamics, serial testing and evolution on treatment

in 322 colorectal cancer patients.

6/3

 

8 a.m. - 11 a.m.

3566

Genomic testing and treatment landscape in patients (pts) with advanced

non-small cell lung cancer (aNSCLC) using real-world data from community

oncology practices

6/3

 

1:15 p.m. - 4:15 p.m.

1585

Correlation of circulating tumor DNA (ctDNA), tissue-based genomic

profiling and clinical efficacy in the biomarker directed Ph1b trial in

metastatic bladder cancer (BISCAY).

6/3

 

1:15 p.m. - 4:15 p.m.

4553

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been used by more than 6,000 oncologists, over 50 biopharmaceutical companies and all 28 of the National Comprehensive Cancer Network centers.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the expected impact of data to be presented at upcoming scientific congresses. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2018 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Investor Contact:

Lynn Lewis or Carrie Mendivil

investors@guardanthealth.com

Media Contact:

Josh Wein or Ian Stone

press@guardanthealth.com

GHLogo2018F.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
21 May
VELO
Så er der lidt at læse på. . Se bla.. Purpose: Tacrolimus extended release (TacER) (Envarsus XR®) ha..
21
17 May
VELO
Hej Alle,   Har siddet og kigget på regnskabet, for at finde ud af hvordan 2019 ender. Umiddelbart e..
18
14:03
VELO
Har modtaget data, som viser en stigning i receptal på 20% siden Januar 2019.  
17
20 May
PNDORA
Paa trods af et godkendt Q1 regnskab, er aktien faldet som en sten. Markedet er ligeglad med Pandora..
17
18 May
VWS
Ditlev.. Havde store ambitioner, og store armbevægelser .. Ikke alt gik godt.. Men finanskrisen kan..
17
22 May
VWS
Vestas secures 44 MW order for V120-2.2 MW turbines with tall tower solution News release from Ves..
16
20 May
DANSKE
Hører på Radio247 at Jyske Bank er indblandet i momssvindel via et par kunder. Penge ud og ind på en..
15
18 May
ZEAL
Nedenfor er det samlet udskift af Q1 telefonkonferencen for Zealand Pharma.    Jeg har først trukket..
15
18 May
AMBU-B
Cook Medical er en førende amerikansk medicovirksomhed med en omsætning på ca. 2 mia. usd og aktivit..
14
18 May
VELO
Jeg er meget uenig med dig Munch. For mig er toplinjen klart mest interessant lige nu, for det er de..
14

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Floor & Decor Holdings, Inc. (NYSE: FND) and Encourages Floor & Decor Investors to Contact the Firm
2
Nokia and U Mobile deploy Single RAN Advanced Network to expand LTE services and collaborate on 5G live network trial in Malaysia
3
PayPoint plc: Preliminary results
4
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for The Boeing Company Investors
5
Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 May 2019 21:17:29
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190514.2 - EUROWEB6 - 2019-05-23 22:17:29 - 2019-05-23 21:17:29 - 1000 - Website: OKAY